Cancer Research AACR Conference on Molecular Diagnostics - 2008  Tumor Immunology: New Perspectives
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Trikha, M.
Right arrow Articles by Nakada, M. T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Trikha, M.
Right arrow Articles by Nakada, M. T.
[Cancer Research 62, 2824-2833, May 15, 2002]
© 2002 American Association for Cancer Research


Experimental Therapeutics

Multiple Roles for Platelet GPIIb/IIIa and {alpha}vß3 Integrins in Tumor Growth, Angiogenesis, and Metastasis

Mohit Trikha1, Zhao Zhou, Jozsef Timar, Erzebet Raso, Margaret Kennel, Eva Emmell and Marian T. Nakada

Department of Biology Research, Centocor, Inc., Malvern, Pennsylvania 19355 [M. T., Z. Z., M. K., E. E., M. T. N.], and Department of Tumor Progression, National Institute of Oncology, Budapest, Hungary H-1122 [J. T., E. R.]

In vivo tumor cells interact with a variety of host cells such as endothelial cells and platelets, and these interactions are mediated by integrins GPIIb/IIIa and {alpha}vß3. We used chimeric (c) 7E3 Fab (ReoPro) and murine (m) 7E3 F(ab')2 to elucidate the role of these integrins in angiogenesis, tumor growth, and metastasis. These antibodies are potent inhibitors of GPIIb/IIIa and {alpha}vß3. c7E3 Fab inhibited {alpha}vß3-mediated human umbilical vein endothelial (HUVEC) and melanoma cell adhesion, migration, invasion, and basic fibroblast growth factor stimulated proliferation of HUVECs (IC50 values range from 0.15 to 5 µg/ml for different assays). In an in vitro angiogenesis assay, c7E3 Fab inhibited basic fibroblast growth factor and platelet-stimulated capillary formation of HUVECs (IC50 = 10 µg/ml and 15 µg/ml, respectively), demonstrating that endothelial {alpha}vß3 is important for sprouting, and platelet-stimulated sprouting is mediated by GPIIb/IIIa. In an experimental metastasis assay, a single pretreatment of human melanoma cells with c7E3 Fab (2.5 µg/ml) inhibited lung colonization of the tumor cells in severe combined immunodeficient mice. In vivo, m7E3 F(ab')2 partially inhibited growth of human melanoma tumors in nude mice compared with control-treated animals. These data suggest that tumor cell-expressed integrins are important but not the only component involved in tumor growth. Because c7E3 Fab and m7E3 F(ab')2 do not cross-react with murine integrins, this inhibition of metastasis and tumor growth is attributable to direct blockade of human tumor {alpha}vß3 integrins. m7E3 F(ab')2 completely blocked tumor formation and growth of human melanoma tumors growing in nude rats. In this xenograft model, m7E3 F(ab')2 simultaneously binds to both human tumor and host platelet GPIIb/IIIa and endothelial {alpha}vß3 integrins, thus participating as an antiangiogenic and an antitumor agent. Collectively, these results indicate that combined blockade of GPIIb/IIIa and {alpha}vß3 affords significant antiangiogenic and antitumor benefit.




This article has been cited by other articles:


Home page
J. Leukoc. Biol.Home page
N. Li
Platelet-lymphocyte cross-talk
J. Leukoc. Biol., May 1, 2008; 83(5): 1069 - 1078.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
T. J. MacDonald, C. F. Stewart, M. Kocak, S. Goldman, R. G. Ellenbogen, P. Phillips, D. Lafond, T. Y. Poussaint, M. W. Kieran, J. M. Boyett, et al.
Phase I Clinical Trial of Cilengitide in Children With Refractory Brain Tumors: Pediatric Brain Tumor Consortium Study PBTC-012
J. Clin. Oncol., February 20, 2008; 26(6): 919 - 924.
[Abstract] [Full Text] [PDF]


Home page
GlycobiologyHome page
A. Cumashi, N. A. Ushakova, M. E. Preobrazhenskaya, A. D'Incecco, A. Piccoli, L. Totani, N. Tinari, G. E. Morozevich, A. E. Berman, M. I. Bilan, et al.
A comparative study of the anti-inflammatory, anticoagulant, antiangiogenic, and antiadhesive activities of nine different fucoidans from brown seaweeds
Glycobiology, May 1, 2007; 17(5): 541 - 552.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
Y. Yu, E. Davicioni, T. J. Triche, and G. Merlino
The Homeoprotein Six1 Transcriptionally Activates Multiple Protumorigenic Genes but Requires Ezrin to Promote Metastasis
Cancer Res., February 15, 2006; 66(4): 1982 - 1989.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
A. Abdollahi, D. W. Griggs, H. Zieher, A. Roth, K. E. Lipson, R. Saffrich, H.-J. Grone, D. E. Hallahan, R. A. Reisfeld, J. Debus, et al.
Inhibition of {alpha}v{beta}3 Integrin Survival Signaling Enhances Antiangiogenic and Antitumor Effects of Radiotherapy
Clin. Cancer Res., September 1, 2005; 11(17): 6270 - 6279.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
J. J. Bergh, H.-Y. Lin, L. Lansing, S. N. Mohamed, F. B. Davis, S. Mousa, and P. J. Davis
Integrin {alpha}V{beta}3 Contains a Cell Surface Receptor Site for Thyroid Hormone that Is Linked to Activation of Mitogen-Activated Protein Kinase and Induction of Angiogenesis
Endocrinology, July 1, 2005; 146(7): 2864 - 2871.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
J. S. Palumbo, K. E. Talmage, J. V. Massari, C. M. La Jeunesse, M. J. Flick, K. W. Kombrinck, M. Jirouskova, and J. L. Degen
Platelets and fibrin(ogen) increase metastatic potential by impeding natural killer cell-mediated elimination of tumor cells
Blood, January 1, 2005; 105(1): 178 - 185.
[Abstract] [Full Text] [PDF]


Home page
Br. J. Radiol.Home page
N Cordes and V Meineke
Modification of the cellular radiation survival and proliferation response by cell-matrix interactions: implications for integrin targeting in therapeutic approaches for radiation accident patients
Br. J. Radiol., January 1, 2005; Supplement_27(1): 152 - 156.
[Abstract] [Full Text] [PDF]


Home page
Endocr. Rev.Home page
H. E. Turner, A. L. Harris, S. Melmed, and J. A. H. Wass
Angiogenesis in Endocrine Tumors
Endocr. Rev., October 1, 2003; 24(5): 600 - 632.
[Abstract] [Full Text] [PDF]


Home page
JNCI J Natl Cancer InstHome page
S. E. Bojesen, A. Tybjaerg-Hansen, and B. G. Nordestgaard
Integrin {beta}3 Leu33Pro Homozygosity and Risk of Cancer
J Natl Cancer Inst, August 6, 2003; 95(15): 1150 - 1157.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
M. M. Fuster, J. R. Brown, L. Wang, and J. D. Esko
A Disaccharide Precursor of Sialyl Lewis X Inhibits Metastatic Potential of Tumor Cells
Cancer Res., June 1, 2003; 63(11): 2775 - 2781.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2002 by the American Association for Cancer Research.